Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Liabilities and Shareholders Equity (2017 - 2025)

KalVista Pharmaceuticals' Liabilities and Shareholders Equity history spans 11 years, with the latest figure at $250.8 million for Q2 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 6.53% to $250.8 million in Q2 2025 year-over-year; TTM through Apr 2025 was $906.6 million, a 39.81% increase, with the full-year FY2025 number at $250.8 million, up 6.53% from a year prior.
  • Liabilities and Shareholders Equity hit $250.8 million in Q2 2025 for KalVista Pharmaceuticals, down from $294.8 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for KALV hit a ceiling of $294.8 million in Q4 2024 and a floor of $66.2 million in Q1 2021.
  • Historically, Liabilities and Shareholders Equity has averaged $188.8 million across 4 years, with a median of $183.2 million in 2023.
  • The widest YoY moves for Liabilities and Shareholders Equity: up 193.98% in 2021, down 35.68% in 2021.
  • Tracing KALV's Liabilities and Shareholders Equity over 4 years: stood at $272.0 million in 2021, then plummeted by 48.99% to $138.7 million in 2023, then soared by 112.49% to $294.8 million in 2024, then dropped by 14.94% to $250.8 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for KALV at $250.8 million in Q2 2025, $294.8 million in Q4 2024, and $160.8 million in Q4 2024.